Coalition asks for agency leader with industry experience
This article was originally published in The Tan Sheet
Executive Summary
The Department of Health and Human Services secretary-designate should not disqualify FDA commissioner candidates "due to relationships with industry during the course of his/her career," a group of health organizations called the "FDA Commissioner Coalition" in media reports says in a letter to former Sen. Tom Daschle. Experience within "an FDA-regulated industry should be viewed as a positive qualification," as should solid scientific credentials, the ability to build consensus and a commitment to advance evidence-based science in the area of drug development, says the coalition, which includes groups with industry ties. Biotechnology and pharmaceutical stakeholders voiced concern over the Obama administration leaning toward an FDA head hostile to industry (1"The Tan Sheet" Nov. 10, 2008, p. 3). Groups signing the letter include the Alliance for Aging Research, the American Cancer Society and WomenHeart
You may also be interested in...
With Democrat In White House, “More Aggressive” FDA Comes Into Focus
Democratic control of the White House, Senate and House brings the potential of a "more aggressive" FDA into sharp focus
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.